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1. Introduction 
Pyruvate kinase (PyK) (EC 2.7.1.40) which cataly- 
ses one of the three physiologically irreversible steps 
in glyolysis has been studied in animals uch as rat 
where it occurs in three different isoenzymic forms 
[1 ]. Rat liver has two PyK isoenzymes one form 
termed type L is under hormonal and dietary regula- 
tion whereas the other form type M 2 is not and more 
closely resembles the third PyK isoenzyme, type M 1 
which is present in muscle and brain. The three types 
of PyK have distinct kinetic properties and react dif- 
ferently with several metabolites such as ATP, fructose 
1, 6-diphosphate and amino acids. For instance, L type 
PyK is activated by fructose 1,6-diphosphate and in- 
hibited by ATP whereas type M 1 is not. 
In this paper we describe the purification from hu- 
man placenta of a distinct PyK isoenzyme with prop- 
erties different from PyK in human liver and muscle. 
The placental isoenzyme of PyK has a number of fea- 
tures in common with PyK from some human tumours. 
2. Materials and methods 
2.1. Tissues 
Human placentae were obtained immediately after 
vaginal deliveries, at term, from uncomplicated preg- 
nancies; amnion and cord were discarded and the re- 
maining tissue was exhaustively washed in cold 0.9% 
NaC1 to remove all traces of blood. Other human tis- 
sues were operation or post-mortem specimens and 
after thorough washing in cold 0.9% NaC1 were stored 
at -20°C. Biopsy speciments of diagnosed carcinoma 
were obtained from one male and one female with 
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carcinoma of the lung, a male and female with stom- 
ach carcinoma nd a male with carcinoma of the je- 
junum; these tissues were also exhaustively washed 
as before. 
2.2. Preparation of  extracts 
For routine enzyme determinations, chromatog- 
raphy and electrophoresis, tissues were extracted 
with 1 vol of 0.1 M phosphate buffer, pH 7.4 (con- 
raining 1 mM dithiothreitol and 2 mM EDTA) in a 
Sorvall omnimix for 2 min at 4°C. The homogenate 
was then centrifuged at 35 000 g for 30 rain and the 
clear supernatant was retained. 
2.3. Electrophoresis 
Horizontal-starch gel electrophoresis was used to 
separate PyK isoenzymes which were then detected 
in sittron the gels as described previously [2]. Elec- 
trophoresis was carried out in 14% starch gels pre- 
pared in 5 mM Tris-maleate buffer, pH 8.4, (con- 
taining 1 mM dithiothreitol and 2 mM EDTA). The 
bridge buffer was 0.1 M Tris-maleate and electro- 
phoresis was carried out for 16 hr at 6 V/cm of eel 
at 4°C, as before [2]. 
2.4. PyK assay 
PyK activity was measured spectrophotometrically 
at pH 7.4 in 0.16 M triethanolamine-HC1 buffer with 
lactate dehydrogenase as before [2]. Enzyme activity 
is expressed in Intemational Units per mg protein 
which was measured by the method of Low~ et al. 
[31. 
2.5. Reagents 
All chemicals were the purest grades available. The 
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amino acids were chromatographically pure samples, 
supplied by Calbiochem. Nucleotide phosphates were 
obtained from Boehringer (Mannheim) and fructose 
1,6-diphosphate from Sigma Chemical Co. 
3. Results 
3.1. Purification of PyK from placenta 
All operations were carried out at 4°C. Placenta 
(300 g) was extracted for 2 min in a Sorvall Omnimix 
with an equal volume of 0.1 M phosphate buffer pH 
7.4 Containing 2.5 mM dithiothreitol and 2 mM EDTA. 
The homogenate was then centrifuged at 35 000 g for 
30 min and solid (NH4)2SO 4, 35% (w/v) was added 
very slowly with shaking to the clear supernatant. Af- 
ter standing for 2 hr the extract was centrifuged at 
12 000 g for 15 min. After the precipitate was discard- 
ed the supernatant was brought o 42% (w/v) with 
solid (NH4)2SO 4 and allowed to stand for a further 
2 hr, after which it was centrifuged at 12 000 g for 
15 min. The supernatant was discarded and the precip- 
itate dissolved with stirring in a minimal volume of 
20 mM Tris-HC1 buffer, pH 7.4 (containing 1mM 
dithiothreitol) and dialysed for 12 hr against several 
changes of the same buffer. 
After dialysis, the extract was placed on a CM-cellu- 
lose column (1.5 cm × 12 cm). previously equilibrated 
with 0.1 M imidazole buffer, pH 5.9 (containing 0.1 M 
KC1 and 1 mM dithiothreitol). The enzyme was eluted 
from the column with the same buffer. 
Fractions from the CM-cellulose column which con- 
tained PyK were applied directly to a DEAE-Sephadex 
A-50 column, previously equilibriated with 0.02 M 
Tris-HC1, pH 7.4 (containing 0.1 M KC1, 0.1 M MgC12 
and 1 mM dithiothreitol). The enzyme was eluted with 
the same buffer. 
Fractions containing the enzyme were pooled, 
concentrated with solid (NH4)2SO 4 and the resulting 
precipitate dissolved in a minimal amount of 0.1 M 
phosphate buffer, pH 7.4, and dialysed for 12 hr, 
against several changes of the same buffer. Enzyme 
solution (1 ml) was applied to a column (2 × 58 cm, 
bed volume, 190 ml) of Sephadex G-200 and eluted 
with 0.1 M phosphate buffer, pH 7.4 (containing 
0.9% NaC1 + 2 mM dithiothreitol). Fractions contain- 
ing the enzyme were pooled and stored at -20°C. As 
shown in table 1 the overall purification was 190-fold. 
3.2. Partial purification of PyK from other tissues 
PyK was partially purified from the following hu- 
man tissues; five tumours, muscle, liver, stomach, in- 
testine and lung by chromatography on Sephadex 
G-200. Each column (2 X 58 cm; bed volume, 190 ml) 
was equilibrated with 0.1 M phosphate buffer, pH 7.4 
(containing 0.9% NaC1 and 2 mM dithiothreitol). One 
ml of tissue extract (see section 2.2.) was applied to 
the column and PyK was eluted with the quilibrating 
buffer-mixture. A partial purification of about 40-fold 
was obtained in this way and small molecules uch as 
amino acids and organic phosphates were removed. 
The specific activities of tumour PyK were over 3-fold 
greater than those of the tissues of origin of the tu- 
mours. These partially purified extracts were used in 
subsequent s udies. 
3.3. Properties of PyK from placenta nd other tissues 
3.3.1. Stability 
PyK from human muscle, stomach, intestine and 
lung was relatively stable and could be stored for sev- 
eral weeks at 4°C with little loss in activity. PyK from 
human liver, in contrast, was highly unstable and lost 
up to 90% of its original activity after 15 hr at 4°C. 
Placental and tumour PyK were more stable than the 
Table 1 
Purification of pyruvate kinase from human placenta. 
Stage of Purification Volume Total activiW Total protein Specific a tivity Purification Yield 
(ml) (EU.) (mg) (units/mg protein) (Fold) % 
Original Supernatant 280 1456 364 000 0.04 1 100 
(NH4)2 SO 4 ppt. 38 2148 2972 0.73 18 148 
CM-ceUulose 30 1760 619 2.8 70 120 
DEAE-sephadex 24 1512 420 3.6 91 104 
Sephadex G-200 10 152 20 7.6 190 10 
282 
Volume 37, number 2 FEBS LETTERS 
Table 2 
Influence of various ubstances on pyruvate kinase from different human tissues and tumours*. 
December 1973 
Pyruvate kinase from: 
Tumours** Placenta Muscle Liver Stomach Lung Small intestine 
Substance Concentration 
Alanine 10-6M 80-100% 100% No effect No effect No effect No effect No effect 
Inhibition Inhibition 
Phenylalaninel" 10-5M 84-100% 100% No effect No effect No effect No effect No effect 
Inhibition Inhibition 
Serine 10-5M 82-305% 200-300% No effect No effect No effect No effect No effect 
Activation Activation 
ATP 4.2 X 10-3M No effect No effect 10% 50% - - - 
Inhibition Inhibition 
Fructose 4.2 × 10-3M - - No effect 400% No effect No effect No effect 
Activation 
1,6-diphosphate 10-6M 72-111% 60-80% - No effect - - - 
Activation Activation 
*For inhibition and activation studies, 0.01 ml of the above substances were incubated with 0.2 ml of enzyme solution in 2.5 ml 
0.16 M triethanolamine buffer, pH 7.4, at 30°C. Enzyme activity was measured after 15 min. 
**Because there was an overall similarity in the behaviour of pyruvate kinase from the five tumours, the results are presented un- 
der one heading and the range of inhibition or activation isgiven. The figures for placenta represent results of five separate ex- 
periments with different placentae. The experiment with human muscle and liver were repeated once and good agreement was 
obtained. The remaining values for stomach, lung and small intestine are results from one experiment. 
"~ At higher concentrations of phenylalanine (4.2 X 10 -3  M) over 90% inhibition of muscle and stomach pyruvate kinase was ob- 
tained. 
liver enzyme and lost about 30% of their original acti- 
vity after 15 hr at 4°C. For these studies on stability, 
enzyme solutions were stores in 0.1 M phosphate buf- 
fer, pH7.4  (containing 0.9% NaCI and 2 mM dithio- 
threitol). 
3.3.2. Influence of ATP, amino acids, etc. on PyK. 
ATP, fructose 1,6.diphosphate, alanine and pheny- 
lalanine are known to influence the activities of PyK 
isoenzymes in rat tissues [1 ]. The effects of  these com- 
pounds on PyK from various human tissues are shown 
in table 2. In common with PyK in similar tissues from 
rat, PyK from human liver was inhibited by ATP and 
activated by fructose 1,6-diphosphate whereas the mus- 
cle PyK was not affected by the latter and only slightly 
inhibited by ATP. In contrast, PyK from placenta re- 
acted in a different manner with these aforementioned 
compounds and showed a striking resemblance to tu- 
mour PyK (table 2). 
Likewise, phenylalanine and alanine inhibited both 
placental and tumour PyK while serine activated the 
isoenzyme from both of  the latter tissues. These amino 
acids, at concentrations of 10 -5  or 10 -6  M, had no 
effect on PyK from human liver, muscle, stomach, in- 
testine and lung (table 2). 
3.3.3. Electrophoresis 
A zymogram of PyK from various human tissues 
is shown in fig. 1. Placental and tumour PyK had the 
same electrophoretic mobil ity which was quite distinct 
from PyK in other human tissues including the tissues 
of origin of the tumour. The electrophoretic mobil ity 
of the cationic isoenzyme of PyK was 10 mm from the 
origin in tissues uch as lung, stomach, muscle, liver 
and small intestine whereas the comparable figure for 
tumours and placenta was 16 mm. This result was re- 
peated on at least five occasions. 
3.3.4. Molecular weight 
The apparent molecular weight of PyK from pla- 
centa and human muscle was determined with Sepha- 
dex G-200 calibrated with the following: cyt.ochrome 
c (12 400), ovalbumin (45 000), bovine serum albumin 
(67 000), yeast hexokinase (96 000), lactate dehydro- 
genase (rabbit muscle, 135 000), catalase (248 000), 
R-phycocyanin (270 000) and R-phycoerythrin 
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Fig. 1. Starch gel electrophoresis patterns of pyruvate kinase 
from various human tissues. For details ee text: 1 = Stomach, 
small intestine, lung, heart, brain; 2 = muscle; 3= liver; 4 = pla- 
centa nd tumour. 
(291 000). Human placental PyK had a lower molecu- 
lar weight (126 000) than either PyK from human mus- 
cle (202 000) or rabbit muscle (230 000). 
4. Discussion 
These studies represent, o our knowledge, the first 
description of the purification and properties of PyK 
from term placenta, a tissue where the Embden-Meyer- 
hof pathway accounts for the vast majority of glucose 
metabolised [4]. The present results have also shown 
that based on a number of different criteria, human 
placental PyK is different from other human tissues 
including liver and muscle. The latter two organs con- 
tain between them the full complement of PyK iso- 
enzymes present in rat tissues [1 ]. The placental PyK 
isoenzyme may represent another example of the syn- 
thesis of a specific isoenzyme by this organ which 
elaborates, for instance, adistinct heat stable alkaline 
phosphatase [5]. The similarity between placental PyK 
and tumour PyK (table 2 and fig. 1) is also interesting 
in view of the elaboration by human tumours of pla- 
cental proteins including the aforemenIioned alkaline 
phosphatase [6]. Many animal tumours contain isoen- 
zymes with distinct properties from the tissue of origin 
of the tumours [7]. In this regard it is of interest hat 
rat hepatomas contain a distinct PyK isoenzyme quite 
different from PyK isoenzymes in liver and muscle 
[8,9]. Also a recent preliminary communication has 
suggested, on the basis of electrophoretic and kinetic 
data, that a distinct PyK isoenzyme xists in human 
tumours [10]. 
Although additional studies are necessary to fur- 
ther characterize placental PyK, these results, in our 
opinion, do provide evidence for the presence of a 
distinct PyK isoenzyme in human placenta. They also 
indicate that a considerable degree of similarity exists 
between placental PyK and PyK from five human tu- 
mours. The presence of a distinct PyK isoenzyme in 
placenta ndtumours could have important diagnos- 
tic applications especially if this isoenzyme scapes 
from these tissues into the circulation. 
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